SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (TSXV:SGMD) announced that it will hold an earnings conference call (see details below) to discuss its first quarter 2023 financial results, including details on organic growth for the quarter, deal flow, and acquisition integration status, on Tuesday, May 16, 2023 at 5:00 pm (Eastern Time) and will issue an earnings press release earlier that morning.
Conference call/Webcast Information:
Fiscal Third Quarter Earnings Call Dial In: +1 (800) 245-3047
Direct/International Dial In: 203-518-9765
Conference ID: SALONA
For more information please contact:
Luke Faulstick
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
| Last Trade: | C$0.13 |
| Daily Volume: | 0 |
| Market Cap: | C$7.480M |
November 25, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
